Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1).


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
14 Mar 2019
Historique:
received: 07 12 2018
accepted: 14 02 2019
entrez: 21 3 2019
pubmed: 21 3 2019
medline: 21 3 2019
Statut: epublish

Résumé

In order to study the role of S1PRs in inflammatory skin disease, S1PR modulators are dosed orally and topically in animal models of disease. The topical application of S1PR modulators in these models may, however, lead to systemic drug concentrations, which can complicate interpretation of the observed effects. We set out to design soft drug S1PR modulators as topical tool compounds to overcome this limitation. A fast follower approach starting from the drug ponesimod allowed the rapid development of an active phenolic series of soft drugs. The phenols were, however, chemically unstable. Protecting the phenol as an ester removed the instability and provided a compound that is converted by enzymatic hydrolysis in the skin to the phenolic soft drug species. In simple formulations, topical dosing of these S1PR modulators to mice led to micromolar skin concentrations but no detectable blood concentrations. These topical tools will allow researchers to investigate the role of S1PR in skin, without involvement of systemic S1PR biology.

Identifiants

pubmed: 30891137
doi: 10.1021/acsmedchemlett.8b00616
pmc: PMC6421539
doi:

Types de publication

Journal Article

Langues

eng

Pagination

341-347

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Drug Metab Rev. 2001 Aug-Nov;33(3-4):273-97
pubmed: 11768770
Drug Metab Dispos. 2004 Nov;32(11):1201-8
pubmed: 15304429
J Invest Dermatol. 2009 Aug;129(8):1954-62
pubmed: 19194476
Drug Discov Today. 2009 Nov;14(21-22):1011-20
pubmed: 19729075
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
J Med Chem. 2010 May 27;53(10):4198-211
pubmed: 20446681
J Med Chem. 2011 Oct 13;54(19):6888-904
pubmed: 21870878
J Dermatol Sci. 2013 Jul;71(1):29-36
pubmed: 23643308
Nat Rev Drug Discov. 2013 Sep;12(9):688-702
pubmed: 23954895
Biomolecules. 2013;3(3):null
pubmed: 24286034
J Med Chem. 2014 Jul 24;57(14):5893-903
pubmed: 24984230
Allergo J Int. 2014;23(2):54-59
pubmed: 26120515
J Med Chem. 2017 Jan 26;60(2):767-786
pubmed: 27983835
Bioorg Med Chem Lett. 2018 Oct 15;28(19):3255-3259
pubmed: 30143424

Auteurs

Mark Bell (M)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

David Foley (D)

Medicines Discovery Institute, Cardiff University, Cardiff CF10 3XQ, U.K.

Claire Naylor (C)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Gavin Wood (G)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Colin Robinson (C)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Jennifer Riley (J)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Ola Epemolu (O)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Lucy Ellis (L)

New Modalities, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg SE-431 83, Sweden.

Paul Scullion (P)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Yoko Shishikura (Y)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Maria Osuna-Cabello (M)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Liam Ferguson (L)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Erika Pinto (E)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Daniel Fletcher (D)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Elad Katz (E)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

W H Irwin McLean (WHI)

Dermatology and Genetic Medicine, Division of Molecular Medicine, University of Dundee, Dundee DD1 5EH, U.K.

Paul Wyatt (P)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Kevin D Read (KD)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Andrew Woodland (A)

Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dow Street, Dundee DDI 5EH, U.K.

Classifications MeSH